The complexity of turning a new drug into a successful asset remains a hurdle even beyond FDA approval. Explore why nailing the launch of new medicines has become increasingly critical in
this Trendline.
AstraZeneca is dropping a COVID-19 prevention therapy by the wayside amid the emergence of new variants. The pharma giant said it’s no longer seeking FDA approval for its monoclonal antibody — instead it’s placing more of its R&D bets in oncology.
By 2030, AstraZeneca is aiming to treat more than half of all patients with lung cancer around the world. From the PD-L1 inhibitor Imfinzi to the antibody-drug conjugate Enhertu, AstraZeneca has approached lung cancer from several different angles, including therapies that target specific mutations. In particular, the company has a decadeslong history in EGFR-mutated lung cancer.
Today, we’re looking at AstraZeneca’s EGFR-mutated non-small cell lung cancer portfolio, and at how the company built an oncology powerhouse on just one target.
Thanks for reading.
Michael Gibney Senior Editor & Writer, PharmaVoice Email
Before an AI-discovered drug proves its worth in the clinic, the technology is shining in other areas such as diagnostics and data management. Explore the latest use cases for AI in life sciences in this Trendline.
The rundown from yesterday
Yesterday, we looked at a PBM reform approach that could save the country billions.
Biosimilar manufacturers face pressure to optimize processes and control costs. Discover strategies to boost efficiency and competitiveness in biopharma production in this webinar.
